Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
暂无分享,去创建一个
Melissa L. Johnson | P. Janne | Dong-Wan Kim | J. Yang | Sang-We Kim | D. Sternberg | M. Nishio | K. Gold | H. Murakami | Channing Yu | C. Baik | H. Hayashi | Helena A. Yu | C. Steuer | M. Koczywas | Zhenhao Qi | Wu-Chou Su | Yang Qiu | Lihui Zhao | R. Shi | M. Vigliotti | H. Yu | M. Johnson
[1] S. Ou,et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. , 2021 .
[2] P. Jänne,et al. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions , 2021, Clinical Cancer Research.
[3] S. Chandarlapaty,et al. Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.
[4] T. Forshew,et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) , 2020, Journal for ImmunoTherapy of Cancer.
[5] P. Janne,et al. Abstract 5192: EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402 , 2020 .
[6] K. Suresh,et al. Pulmonary toxicity of systemic lung cancer therapy , 2020, Respirology.
[7] Y. Bang,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. , 2020, The New England journal of medicine.
[8] L. Sequist,et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. , 2020, The Lancet. Oncology.
[9] D. Pe’er,et al. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer , 2020, Clinical Cancer Research.
[10] K. Hansen,et al. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. , 2019, Lung cancer.
[11] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[12] Ying Cheng,et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.
[13] M. Tiseo,et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. , 2019, Critical reviews in oncology/hematology.
[14] M. Murakami,et al. A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization , 2019, Clinical Cancer Research.
[15] Y. Matsumura,et al. U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer , 2019, Molecular Cancer Therapeutics.
[16] M. Westphal,et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients , 2019, Scientific Reports.
[17] H. Iwata,et al. Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] T. Agatsuma,et al. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. , 2019, Chemical & pharmaceutical bulletin.
[19] R. Rosell,et al. EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients , 2018 .
[20] K. Nishio,et al. An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC , 2018, Oncogene.
[21] J. Barrett,et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Barrett,et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] M. Ahn,et al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Han,et al. Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review , 2018, OncoTargets and therapy.
[25] J. Shih,et al. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer , 2018, Molecular Cancer.
[26] B. Goh,et al. Third generation EGFR TKIs: current data and future directions , 2018, Molecular Cancer.
[27] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[28] Li Wu,et al. Prognostic significance of HER3 in patients with malignant solid tumors , 2017, Oncotarget.
[29] J. Hung,et al. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy , 2017, BMC Pharmacology and Toxicology.
[30] M. Tiseo,et al. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. , 2016, Translational lung cancer research.
[31] K. Wang,et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.
[32] T. Agatsuma,et al. Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.
[33] T. Agatsuma,et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.
[34] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[36] H. Sasaki,et al. ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. , 2008, The Journal of surgical research.